INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,242 | -6.8% | 295,608 | +23.6% | 0.00% | 0.0% |
| Q2 2023 | $1,332 | +25.0% | 239,200 | +28.5% | 0.00% | +100.0% |
| Q1 2023 | $1,066 | +291.9% | 186,100 | -28.1% | 0.00% | – |
| Q4 2022 | $272 | -99.9% | 258,900 | +66.6% | 0.00% | -100.0% |
| Q3 2022 | $416,000 | -26.2% | 155,400 | +31.4% | 0.00% | 0.0% |
| Q2 2022 | $564,000 | +1051.0% | 118,300 | +894.1% | 0.00% | – |
| Q1 2022 | $49,000 | – | 11,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |